Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03XEY
|
|||
| Former ID |
DIB003828
|
|||
| Drug Name |
Epstein-barr virus-specific immunotherapy
|
|||
| Synonyms |
Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)
Click to Show/Hide
|
|||
| Indication | Nasopharyngeal carcinoma [ICD-11: 2B6B; ICD-9: 147] | Phase 2 | [1] | |
| Company |
Dana-Farber Cancer Institute Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00834093) A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.